An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Completed
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another non-adjacent organ or part) breast cancer (abnormal tissue that grows and spreads in the body until it kills) participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2014
Locations: Not set, Sedona, Arizona +32 locations
Conditions: Breast Neoplasms
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Completed
The purpose of this research study is to determine the effectiveness of topical steroid therapy (with a drug called dexamethasone) and topical tacrolimus therapy for the treatment of oral chronic Graft-Versus-Host Disease (cGVHD)
Gender:
ALL
Ages:
4 years and above
Trial Updated:
02/24/2014
Locations: Massachusetts General Hospital, Boston, Massachusetts +4 locations
Conditions: Oral Chronic Graft-versus-host Disease
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for acute lymphoblastic leukemia. PURPOSE: Phase III trial to determine the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/18/2014
Locations: Children's Hospital Los Angeles, Los Angeles, California +19 locations
Conditions: Leukemia
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Bone marrow transplantation allows the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without donor bone marrow transplantation in treating infants who have previously untreated acute lymphobla... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
02/18/2014
Locations: Phoenix Children's Hospital, Phoenix, Arizona +50 locations
Conditions: Leukemia
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
Completed
The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer. This study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2014
Locations: Commonwealth Cancer Center, Danville, Kentucky +6 locations
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
Completed
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells. Dexamethasone may increase the effectiveness and decrease the side effects of gefitinib and calcitriol. PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when given together with gefitinib or when given together with gefitinib and dexamethasone in treating patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2014
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with dexamethasone w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2014
Locations: Sparrow Regional Cancer Center, Lansing, Michigan
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the drug. It is not yet known if dexamethasone is more effective with or without oblimersen in treating multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with or without oblimersen in treating patients who have relapsed or refra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2014
Locations: Genta Incorporated, Berkeley Heights, New Jersey
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Terminated
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/02/2014
Locations: Tulane University, New Orleans, Louisiana +17 locations
Conditions: Immune Thrombocytopenic Purpura
Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
Completed
The purpose of this study is to compare the efficacy of the use of oral aprepitant in combination with intravenous ondansetron and dexamethasone with the efficacy provided by the use of oral aprepitant and dexamethasone for preventing vomiting during the first 24-48 hours after breast surgery.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
12/18/2013
Locations: Scott and White Healthcare, Temple, Texas
Conditions: Postoperative Nausea and Vomiting
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow transplantation may allow doctors to give higher doses of radiation therapy and chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of high-dose etoposide and cyclophosphamide plus total-body irradiation followed by bone marrow transplantation in treating pati... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/17/2013
Locations: St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Lymphoma
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Unknown
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how wel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2013
Locations: Arizona Clinical Research Center, Incorporated, Tucson, Arizona +11 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm